Skip to main content
Premium Trial:

Request an Annual Quote

Metabolon, Charles River Partner on Cancer Research

NEW YORK (GenomeWeb News) –Metabolon and Charles River Discovery Services are partnering to advance cancer research.

The deal, which was officially announced this week, leverages Metabolon's metabolomics technology with Charles River's preclinical oncology expertise.

Together, they will provide customers services focused on identifying, characterizing, and validating drug target candidates; pharmacokinetic and pharmacodynamic, tumor growth delay, tumor growth inhibition, survival, combination, and adjuvant study designs; and development of biomarkers for preclinical pharmacodynamic work, patient stratification and selection, and translational models and efficacy.

Financial and other terms of the deal were not disclosed.

Metabolon is a metabolomics-based diagnostics and services firm. Charles River Discovery Services, part of Charles River Laboratories, provides products for early compound in vitro screening and differentiation.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.